As per NPPA Order S.O. 5690(E) dated 17 October 2026, the trade margin on 137 non-scheduled anti-cancer medicines is capped at 30%. Hetero’s revised MRPs take effect on 9 November 2026.
Patients and partners with questions about the revised prices are welcome to speak to their doctor, pharmacist or hospital.
Source: NPPA Order S.O. 5690(E), The Gazette of India, 17 October 2026.
The Generics Alpha Division of Hetero Healthcare is focused on providing a diverse range of quality and accessible generic medicines across multiple therapeutic areas. With a broad-based portfolio designed to address commonly encountered health conditions, the division supports healthcare professionals and patients with dependable treatment options while contributing to greater accessibility of essential medicines.
Its therapeutic portfolio spans key areas including anti-infectives, pain and inflammation management, gastrointestinal care, respiratory conditions, allergy management, and nutritional and supportive therapies. By addressing acute as well as frequently encountered healthcare needs, Generics Alpha plays an important role in supporting day-to-day clinical practice across diverse patient populations.
Backed by Hetero Healthcare’s strong capabilities in pharmaceutical manufacturing, quality, accessibility, and patient-centric healthcare, the Generics Alpha Division strives to make established therapies available to a wider population. Through its multi-therapy portfolio, the division continues to support effective clinical management and Hetero Healthcare’s broader commitment to making quality healthcare more accessible.
View by-
